{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T16:25:50Z","timestamp":1769012750734,"version":"3.49.0"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"36","license":[{"start":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T00:00:00Z","timestamp":1599177600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Comparison of different anticoagulants in blood management and complications with tranexamic acid (TXA) in total hip arthroplasty (THA) is unclear. Our aim was to compare the efficacy and safety among receiving nadroparin calcium, enoxaparin sodium or rivaroxaban after TXA in THA.<\/jats:p>\n            <jats:p>150 patients undergoing primary unilateral THA were received 15\u200amg\/kg intravenous TXA (IV-TXA) before skin incision, followed by 1 of nadroparin calcium (Group A), enoxaparin sodium (Group B), or rivaroxaban (Group C) randomly during hospitalization. The primary outcome was hidden blood loss (HBL). Other outcomes such as the maximum hemoglobin (Hb) drop, total blood loss (TBL), the volume of drainage, transfusion rate, length of hospital stay (LOS), and complications were also compared.<\/jats:p>\n            <jats:p>There were no statistically significant differences in HBL, the maximum hemoglobin (Hb) drop, transfusion rate, and complications among 3 groups. LOS was significantly higher for patients in Group B than Group A (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.026). Neither deep venous thrombosis (DVT) nor pulmonary embolism (PE) occurred in any group.<\/jats:p>\n            <jats:p>There were no differences in efficacy and safety in patients undergoing THA receiving nadroparin calcium, enoxaparin sodium, or rivaroxaban after anti-fibrinolysis with TXA.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000022028","type":"journal-article","created":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T14:28:30Z","timestamp":1598970510000},"page":"e22028","source":"Crossref","is-referenced-by-count":4,"title":["Effect of 3 different anticoagulants on hidden blood loss during total hip arthroplasty after tranexamic acid"],"prefix":"10.1097","volume":"99","author":[{"given":"Zeng-fa","family":"Deng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zi-ji","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pu-yi","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-liang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ai-shan","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-ming","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6233-0652","authenticated-orcid":false,"given":"Yan","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,9,4]]},"reference":[{"key":"R1-20230915","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(07)60457-7","article-title":"The operation of the century: total hip replacement","volume":"370","author":"Learmonth","year":"2007","journal-title":"Lancet (London, England)"},{"key":"R2-20230915","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1007\/s11999-013-3446-0","article-title":"Topical tranexamic acid reduces blood loss and transfusion rates associated with primary total hip arthroplasty","volume":"472","author":"Chang","year":"2014","journal-title":"Clin Orthop Relat Res"},{"key":"R3-20230915","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1503\/cjs.012817","article-title":"Tranexamic acid administration to older patients undergoing primary total hip arthroplasty conserves hemoglobin and reduces blood loss","volume":"61","author":"El Beheiry","year":"2018","journal-title":"Can J Surg"},{"key":"R4-20230915","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/j.1537-2995.2009.02518.x","article-title":"Activity-based costs of blood transfusions in surgical patients at four hospitals","volume":"50","author":"Shander","year":"2010","journal-title":"Transfusion"},{"key":"R5-20230915","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s00264-013-2134-8","article-title":"Antithrombotic prophylaxis in major orthopaedic surgery: an historical overview and update of current recommendations","volume":"38","author":"Kinov","year":"2014","journal-title":"Int Orthop"},{"key":"R6-20230915","doi-asserted-by":"crossref","first-page":"e10720","DOI":"10.1097\/MD.0000000000010720","article-title":"Tranexamic acid use during total hip arthroplasty: a single center retrospective analysis","volume":"97","author":"Stoicea","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"R7-20230915","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1016\/j.arth.2017.02.068","article-title":"Process improvement project using tranexamic acid is cost-effective in reducing blood loss and transfusions after total hip and total knee arthroplasty","volume":"32","author":"Demos","year":"2017","journal-title":"J Arthroplasty"},{"key":"R8-20230915","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ocl.2016.12.001","article-title":"Effect of tranexamic acid on transfusion rates following total joint arthroplasty: a cost and comparative effectiveness analysis","volume":"48","author":"Evangelista","year":"2017","journal-title":"Orthop Clin North Am"},{"key":"R9-20230915","doi-asserted-by":"crossref","first-page":"g4829","DOI":"10.1136\/bmj.g4829","article-title":"Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety","volume":"349","author":"Poeran","year":"2014","journal-title":"BMJ"},{"key":"R10-20230915","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ijsu.2017.07.097","article-title":"Comparison of oral versus intravenous application of tranexamic acid in total knee and hip arthroplasty: a systematic review and meta-analysis","volume":"45","author":"Zhang","year":"2017","journal-title":"Int J Surg"},{"key":"R11-20230915","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.arth.2016.10.015","article-title":"Low risk of thromboembolic events after routine administration of tranexamic acid in hip and knee arthroplasty","volume":"32","author":"Madsen","year":"2017","journal-title":"J Arthroplasty"},{"key":"R12-20230915","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/j.arth.2016.10.026","article-title":"Topical tranexamic acid is equivalent to targeted preoperative autologous blood donation in total hip arthroplasty","volume":"32","author":"Kasparek","year":"2017","journal-title":"J Arthroplasty"},{"key":"R13-20230915","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1080\/17453674.2017.1361131","article-title":"Comparative efficacy and safety of anticoagulants for prevention of venous thromboembolism after hip and knee arthroplasty","volume":"88","author":"Hur","year":"2017","journal-title":"Acta orthopaedica"},{"issue":"(2 Suppl)","key":"R14-20230915","article-title":"Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines","volume":"141","author":"Falck-Ytter","year":"2012","journal-title":"Chest"},{"key":"R15-20230915","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1586\/17474086.2013.853430","article-title":"The use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgery","volume":"6","author":"Rachidi","year":"2013","journal-title":"Expert Rev Hematol"},{"key":"R16-20230915","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.arth.2016.09.021","article-title":"Phase IV study of thromboembolic and bleeding events following hip and knee arthroplasty using oral factor xa inhibitor","volume":"32","author":"Gomez","year":"2017","journal-title":"J Arthroplasty"},{"key":"R17-20230915","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1177\/1076029618772337","article-title":"Comparison of postoperative bleeding in total hip and knee arthroplasty patients receiving rivaroxaban, enoxaparin, or aspirin for thromboprophylaxis","author":"Lindquist","year":"2018","journal-title":"Clin Appl Thromb HemostV 24"},{"key":"R18-20230915","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1302\/0301-620X.99B11.BJJ-2017-0488.R1","article-title":"Multiple boluses of intravenous tranexamic acid to reduce hidden blood loss and the inflammatory response following enhanced-recovery primary total hip arthroplasty: a randomised clinical trial","volume":"99-B","author":"Xie","year":"2017","journal-title":"Bone Joint J"},{"key":"R19-20230915","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1016\/j.arth.2018.04.024","article-title":"Multiple-dose intravenous tranexamic acid further reduces hidden blood loss after total hip arthroplasty: a randomized controlled trial","volume":"33","author":"Lei","year":"2018","journal-title":"J Arthroplasty"},{"key":"R20-20230915","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0968-0160(00)00047-8","article-title":"How much blood is really lost in total knee arthroplasty? Correct blood loss management should take hidden loss into account","volume":"7","author":"Sehat","year":"2000","journal-title":"Knee"},{"key":"R21-20230915","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13018-015-0185-9","article-title":"Hidden blood loss and its influential factors after total hip arthroplasty","volume":"10","author":"Miao","year":"2015","journal-title":"J Orthop Surg Res"},{"key":"R22-20230915","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ijsu.2017.03.031","article-title":"A comparison of combined intravenous and topical administration of tranexamic acid with intravenous tranexamic acid alone for blood loss reduction after total hip arthroplasty: a meta-analysis","volume":"41","author":"Liu","year":"2017","journal-title":"Int J Surg"},{"key":"R23-20230915","doi-asserted-by":"crossref","first-page":"411","DOI":"10.5301\/hipint.5000039","article-title":"Postoperative plasma D-dimer value for predicting deep venous thrombosis following hip arthroplasty with nadroparin prophylaxis","volume":"23","author":"Xu","year":"2013","journal-title":"Hip Int"},{"key":"R24-20230915","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/00000542-198303000-00016","article-title":"Estimating allowable blood loss: corrected for dilution","volume":"58","author":"Gross","year":"1983","journal-title":"Anesthesiology"},{"key":"R25-20230915","first-page":"224","article-title":"Prediction of blood volume in normal human adults","volume":"51","author":"Nadler","year":"1962","journal-title":"Surgery"},{"key":"R26-20230915","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1302\/0301-620X.101B2.BJJ-2018-0898.R1","article-title":"A randomized, double-blind, placebo-controlled trial on the efficacy of tranexamic acid combined with rivaroxaban thromboprophylaxis in reducing blood loss after primary cementless total hip arthroplasty","volume":"101-b","author":"Clav\u00e9","year":"2019","journal-title":"Bone Joint J"},{"key":"R27-20230915","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00264-018-3925-8","article-title":"The efficacy and safety of multiple-dose oral tranexamic acid on blood loss following total hip arthroplasty: a randomized controlled trial","volume":"43","author":"Cao","year":"2019","journal-title":"Int Orthop"},{"key":"R28-20230915","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1080\/08941939.2018.1458166","article-title":"Oxidized regenerated cellulose can reduce hidden blood loss after total hip arthroplasty: a retrospective study","volume":"32","author":"Wang","year":"2019","journal-title":"J Invest Surg"},{"key":"R29-20230915","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1007\/s11999-009-1217-8","article-title":"One intraoperative dose of tranexamic Acid for patients having primary hip or knee arthroplasty","volume":"468","author":"Ralley","year":"2010","journal-title":"Clin Orthop Relat Res"},{"key":"R30-20230915","doi-asserted-by":"crossref","first-page":"e3054","DOI":"10.1136\/bmj.e3054","article-title":"Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis","volume":"344","author":"Ker","year":"2012","journal-title":"BMJ"},{"key":"R31-20230915","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1056\/NEJMoa0800374","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty","volume":"358","author":"Eriksson","year":"2008","journal-title":"N Engl J Med"},{"key":"R32-20230915","first-page":"537","article-title":"Studies on the mechanisms of action of aprotinin and tranexamic acid as plasmin inhibitors and antifibrinolytic agents","volume":"5","author":"Longstaff","year":"1994","journal-title":"Blood Coagul Fibrinolysis"},{"key":"R33-20230915","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20180423","article-title":"Comparison of efficiency and safety of rivaroxaban, apixaban and enoxaparin for thromboprophylaxis after arthroplastic surgery: a meta-analysis","volume":"38","author":"Yu","year":"2018","journal-title":"Biosci Rep"},{"key":"R34-20230915","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/BF00255578","article-title":"Special considerations with regard to the dosage of tranexamic acid in patients with chronic renal diseases","volume":"6","author":"Andersson","year":"1978","journal-title":"Urol Res"},{"key":"R35-20230915","doi-asserted-by":"crossref","DOI":"10.1016\/j.thromres.2012.11.006","article-title":"Duration of postoperative fibrinolysis after total hip or knee replacement: a laboratory follow-up study","volume":"131","author":"Blani\u00e9","year":"2013","journal-title":"Thromb Res"},{"key":"R36-20230915","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.arth.2015.02.009","article-title":"Rivaroxaban vs enoxaparin for venous thromboembolism prophylaxis after hip and knee arthroplasty","volume":"30","author":"Charters","year":"2015","journal-title":"J Arthroplasty"},{"key":"R37-20230915","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s13018-019-1231-9","article-title":"A nested case-control study on the risk factors of deep vein thrombosis for Chinese after total joint arthroplasty","volume":"14","author":"Xu","year":"2019","journal-title":"J Orthop Surg Res"},{"key":"R38-20230915","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1177\/0300060518762281","article-title":"Rivaroxaban versus nadroparin for preventing deep venous thrombosis after total hip arthroplasty following femoral neck fractures: a retrospective comparative study","volume":"46","author":"Zhang","year":"2018","journal-title":"J Int Med Res"},{"key":"R39-20230915","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1160\/TH12-07-0510","article-title":"Efficacy and safety of thromboprophylaxis with low-molecular-weight heparin or rivaroxaban in hip and knee replacement surgery: findings from the ORTHO-TEP registry","volume":"109","author":"Beyer-Westendorf","year":"2013","journal-title":"Thromb Haemost"},{"key":"R40-20230915","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.2106\/JBJS.K.00521","article-title":"Wound complications following rivaroxaban administration: a multicenter comparison with low-molecular-weight heparins for thromboprophylaxis in lower limb arthroplasty","volume":"94","author":"Jameson","year":"2012","journal-title":"J Bone Joint Surg Am"},{"key":"R41-20230915","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1302\/0301-620X.93B1.24987","article-title":"Return to theatre following total hip and knee replacement, before and after the introduction of rivaroxaban: a retrospective cohort study","volume":"93","author":"Jensen","year":"2011","journal-title":"J Bone Joint Surg Br"},{"key":"R42-20230915","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1097\/HS9.0000000000000019","article-title":"Higher adherence to treatment with low-molecular-weight-heparin nadroparin than enoxaparin because of side effects in cancer-associated venous thromboembolism","volume":"2","author":"van der Wall","year":"2018","journal-title":"HemaSphere"},{"key":"R43-20230915","first-page":"5026","article-title":"Venous thromboembolism in cancer patients: still looking for answers","volume":"18","author":"Iorga","year":"2019","journal-title":"Exp Ther Med"},{"key":"R44-20230915","doi-asserted-by":"crossref","first-page":"972","DOI":"10.31925\/farmacia.2018.6.7","article-title":"Modern oral anticoagulant treatment in patients with artial fibrillation and heart failure: insights from the clinical practice","volume":"66","author":"T?ICA","year":"2018","journal-title":"FARMACIA"},{"key":"R45-20230915","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.37358\/RC.19.8.7435","article-title":"Oxidative stress levels, JAK2V617F mutational status and thrombotic complications in patients with essential thrombocythemia","volume":"70","author":"Moisa","year":"2019","journal-title":"Revista De Chimie"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000022028","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T01:14:12Z","timestamp":1694826852000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000022028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,4]]},"references-count":45,"journal-issue":{"issue":"36","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000022028","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,4]]}}}